Abeona Therapeutics Inc.
ABEO Healthcare Biotechnology
Abeona Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.8 million, up 66.3% from fiscal 2023. In the quarter to June 2026, revenue grew 225.1%, EPS fell 116.9%, free cash flow grew 17.1% and total debt fell 23.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow ABEO
Abeona Therapeutics Inc. (ABEO) Piotroski F-score
Abeona Therapeutics Inc.'s Piotroski F-score for fiscal 2025 cannot be worked out: no comparable prior fiscal year (a missing year or a changed year end).
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2023 | 3 | 1.00 |
| FY2022 | 2 | (1.00) |
| FY2018 | 3 | (1.00) |
| FY2017 | 4 | 1.00 |
| FY2016 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | — | — | n/a | — |
| Positive operating cash flow | (76.33m) | — | Fail | 0 |
| Rising return on assets | — | — | n/a | — |
| Cash flow above net income | (147.51m) | — | Fail | 0 |
| Falling long-term leverage | — | — | n/a | — |
| Rising current ratio | 6.93 | — | n/a | — |
| No new shares issued | 52,953,000 | — | n/a | — |
| Rising gross margin | 73.68% | — | n/a | — |
| Rising asset turnover | — | — | n/a | — |
| Piotroski F-score | n/a — no comparable prior fiscal year (a missing year or a changed year end) | — | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| IPSC Century Therapeutics, Inc. compare | 4 |
| EYPT EyePoint, Inc. compare | 3 |
| ABEO Abeona Therapeutics Inc. | — |
| PRLD Prelude Therapeutics Incorporated compare | — |
| NAUT Nautilus Biotechnology, Inc. compare | — |
| XFOR X4 Pharmaceuticals, Inc. compare | — |
| CABA Cabaletta Bio, Inc. compare | — |
| RCKT Rocket Pharmaceuticals, Inc. compare | — |
| PALI Palisade Bio, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover